lyphomed inc said has tentatively agreed form joint venture with privately held novopharm ltd canada whereby each will market drug home country lyphomed will sell novopharm oral pharmaceutical drugs and novopharm will sell lyphomed injectable pharmaceutical drugs canada said joint venture gives lyphomed entry into hospital and retail oral pharmaceutical market with novopharm product line novopharm turn will strengthen its position canadian hospital market using lyphomed injectable products first product marketed will cephalexin monohydrate now marketed eli lilly keflex product whose patent expires april keflex antibiotic with current market excess 250 mln dlrs will made novopharm canada sold new joint venture and distributed lyphomed said reuter 